Beam Therapeutics
Beam Therapeutics Inc. - Common Stock is expected to split Monday, August 15, 2022 with a ratio of 1:5
Beam Therapeutics Inc. - Common Stock recently split on Friday, August 12, 2022 with a ratio of 1:3
At close: Aug 12
After Hours: 7:06PM EDT
Day High/Low65.98 - 69.97
52 Week High/Low27.77 - 82.62
Open / Close66.76 / 69.08
Float / Outstanding61.1M / 70.4M
Vol / Avg.1.6M / 1.3M
Mkt Cap4.9B
50d Avg. Price50.91
Div / Yield-
Payout Ratio-
Total Float61.1M

Beam Therapeutics (NASDAQ:BEAM), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.

Consensus Rating1


Highest Price Target1


Lowest Price Target1


Consensus Price Target1


Analyst Rating Summary1


Analyst Firms Making Recommendations1

  • Cantor Fitzgerald
  • Deutsche Bank
  • Oppenheimer
  • JP Morgan
  • Piper Sandler

1calculated from analyst ratings published within the last 6 months

Analyst Ratings for Beam Therapeutics

All Ratings (0)

Upgrades (0)

Downgrades (0)

Initiations (0)

Analyst Firm
Price Target Change
Rating Change
Previous / Current Rating
Get Alert

Beam Therapeutics Questions & Answers

What is the target price for Beam Therapeutics (BEAM)?

The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by Cantor Fitzgerald on August 12, 2022. The analyst firm set a price target for $4.00 expecting BEAM to fall to within 12 months (a possible -94.21% downside). 100 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Beam Therapeutics (BEAM)?

The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by Cantor Fitzgerald, and Beam Therapeutics initiated their overweight rating.

When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on August 12, 2022 so you should expect the next rating to be made available sometime around August 12, 2023.

Is the Analyst Rating Beam Therapeutics (BEAM) correct?

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a initiated with a price target of $0.00 to $4.00. The current price Beam Therapeutics (BEAM) is trading at is $69.08, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.